TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
StockNews.AI · 3 hours
AI Summary
TransCode Therapeutics reported Phase 1a data for TTX-MC138, showing no dose-limiting toxicities and durable disease stabilization in metastatic cancers. The RP2D is 4.8 mg/kg, and Phase 2a will assess efficacy in ctDNA-positive colorectal cancer after curative-intent therapy, with 16 patients treated and 64% achieving six-month stable disease.
Sentiment Rationale
Positive safety profile and early efficacy signals with a clear Phase 2a catalyst could drive near-term upside for a small-cap RNA-focused name, though risk remains until Phase 2a data readouts.
Trading Thesis
RNAZ could rally within 1–3 quarters on Phase 2a initiation and durable response signals.
Market-Moving
- Phase 2a expansion in ctDNA-positive colorectal cancer slated after Phase 1a results.
- No observed dose-limiting toxicities; RP2D supports safer, earlier trial progression.
- 16 patients treated; 64% with six-month stable disease reinforces efficacy signals.
- miR-10b-targeting RNA therapeutics position RNAZ as a unique oncology RNA play.
Key Facts
- Phase 1a safety endpoints met; no dose-limiting toxicities observed.
- TTX-MC138 (miR-10b inhibitor) shows durable disease control in metastatic cancers.
- RP2D set at 4.8 mg/kg; Phase 2a planned in ctDNA-positive colorectal cancer.
- 16 patients treated; 9 of 14 evaluable (64%) achieved six-month stable disease.
Companies Mentioned
- TransCode Therapeutics, Inc. (RNAZ): Reported Phase 1a safety and activity data; Phase 2a initiation provides near-term upside potential.
- Massachusetts General Hospital (N/A): Provided clinical advisory context; adds credibility but has no direct stock impact.
Industry News
Industry News: material company-specific biotech trial update with a near-term catalyst; fits RNAZ focus on RNA-based cancer therapies.